市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Annovis Bio, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.0
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.00 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 20.40% |
| 机构持股比例 | 8.83% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Quest Partners Llc | 30 Sep 2024 | 46,002 |
| Wescott Financial Advisory Group, Llc | 30 Sep 2024 | 41,607 |
| Sterling Investment Advisors, Ltd. | 30 Sep 2024 | 34,474 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 30.00 (HC Wainwright & Co., 400.00%) | 购买 |
| 中 | 23.00 (283.33%) | |
| 低 | 21.00 (D. Boral Capital, 250.00%) | 购买 |
| 21.00 (EF Hutton, 250.00%) | 购买 | |
| 平均值 | 24.25 (304.17%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 8.29 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 11 Nov 2024 | 21.00 (250.00%) | 购买 | 7.65 |
| HC Wainwright & Co. | 11 Nov 2024 | 30.00 (400.00%) | 购买 | 7.65 |
| 16 Oct 2024 | 30.00 (400.00%) | 购买 | 9.14 | |
| Maxim Group | 25 Oct 2024 | 25.00 (316.67%) | 购买 | 9.87 |
| EF Hutton | 15 Oct 2024 | 21.00 (250.00%) | 购买 | 7.98 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合